撒哈拉以南非洲结核合并症患者利福平暴露的系统综述与荟萃分析
该系统综述与荟萃分析纳入24项研究,评估撒哈拉以南非洲(SSA)及非SSA地区结核合并HIV或糖尿病患者的利福平药代动力学。结果显示所有亚组 pooled Cmax 均低于推荐范围8-24 mg/L,TB-HIV患者AUC最低,提示需个体化给药和TDM。
要点
- SSA地区TB-HIV患者利福平 pooled Cmax 为5.59 mg/L,低于推荐范围8-24 mg/L。
- TB-DM在SSA的Cmax为9.60±4.4 mg/L,高于非SSA的4.27 mg/L。
- TB-HIV患者AUC最低(SSA 29.09 mg/L·h),应优先考虑TDM。
核心结论
- 所有合并症亚组的利福平Cmax均低于推荐范围8-24 mg/L。
- TB-HIV患者AUC最低,应优先实施个体化给药和TDM。
研究设计与样本
- 纳入24项研究,贡献33个合并症亚组进行荟萃分析。
主要发现
- SSA地区TB-HIV的 pooled Cmax 为5.59 mg/L(95%CI 4.59-6.59,I2=97%)。
- 非SSA地区TB-HIV的 pooled Cmax 为5.59 mg/L(95%CI 3.65-6.59)。
- SSA地区TB-DM的Cmax为9.60±4.4 mg/L,非SSA为4.27 mg/L(95%CI 2.77-5.76)。
- TB-HIV的AUC最低,SSA为29.09 mg/L·h(95%CI 21.06-37.13,I2=91%)。
- 异质性高(I2>90%),多数研究(20/23)显示低偏倚风险。
关键数值与推荐
- 推荐Cmax范围为8-24 mg/L,所有亚组 pooled Cmax 均低于此范围。
- SSA地区TB-HIV的Cmax为5.59 mg/L,TB-DM为9.60±4.4 mg/L。
临床怎么用
- 在SSA临床环境中,基于Cmax的TDM更实用,条件允许时可使用AUC。
- 对TB-HIV和TB-DM患者应考虑个体化给药并实施TDM。
局限性
- SSA地区TB-DM仅1个亚组,TB-营养不良无数据。
- 研究间异质性高(I2>90%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Emerging evidence suggests that comorbidities like human immunodeficiency virus (HIV) infection, diabetes mellitus (DM), and malnutrition in tuberculosis (TB) patients can alter drug concentrations, thereby affecting the treatment outcomes. For these populations, personalised strategies such as therapeutic drug monitoring (TDM) may be essential. We investigated the variations of drug levels within comorbid populations and analysed the differences in patterns observed between sub-Saharan Africa (SSA) and non-SSA regions. METHODS: We performed a systematic review and meta-analysis of rifampicin drug pharmacokinetics (PK) through searches of major databases from 1980 to December 2023. A random-effects meta-analysis model using R-studio version 4.3.2 was conducted to estimate pooled serum rifampicin exposure (area under the concentration-time curve [AUC], and peak maximum concentration [Cmax]) between patients with TB-HIV infection, and TB-DM. RESULTS: From 3300 articles screened, 24 studies met inclusion criteria, contributing 33 comorbidity subgroups for meta-analysis. In SSA, 14 subgroups assessed rifampicin PK in TB-HIV, 1 in TB-DM, and none in TB-malnutrition. The pooled mean Cmax was below the recommended range (8-24 mg/L) for all subgroups. For TB-HIV, the pooled Cmax was 5.59 mg/L, 95% CI (4.59-6.59), I2 = 97% for SSA populations and 5.59 mg/L, 95% CI (3.65; 6.59) for non-SSA populations. The Cmax for TB-DM in SSA (9.60 ± 4.4 mg/L) exceeded non-SSA (4.27 mg/L, 95% CI [2.77-5.76]). The lowest AUC was in TB-HIV (SSA, 29.09 mg/L h, 95% CI [21.06; 37.13, I2 = 91%]). High variability and heterogeneity (I2 >90%) were observed, with most studies (20/23) showing low bias. CONCLUSION: Our results emphasise the need for individualised dosing and targeted TDM implementation among TB-HIV and TB-DM populations on rifampicin in SSA. Although all populations exhibited low Cmax levels, TB-HIV populations may be prioritised as AUC levels were lowest. In clinical settings in SSA, Cmax-based TDM is more practical, but AUC can be used in treatment where feasible.
引用
- Said B, Pétermann Y, Howlett P, et al. Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment-A Systematic Review and Meta-analysis. Clin Pharmacokinet. 2025. PMID: 40608197. doi:10.1007/s40262-025-01537-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。